Cellectar Biosciences opened at $1.21, in line with its previous close of $1.21. In the last trading session, the stock traded between $1.15 and $1.22. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Cellectar Biosciences is now worth
$ 0.45
Resulting in a loss of
$ 99.55 (99.55%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.05 (-3.72%)
Day High
$1.22
Day Low
$1.15
Day Open
$1.21
Prev Close
$1.21
Volume
50,350
1W Return
-6.35%
1M Return
-18.53%
3M Return
-55.62%
6M Return
-61.93%
1Y Return
-67.28%
Market Cap ($ Mn)
12
PE Ratio
-
PB Ratio
0.70
PEG Ratio
-
ROE
-255.98%
ROCE
-206.25%
EPS (TTM)
$-0.79
1 Week
-6.35%
1 Month
-18.53%
3 Months
-55.62%
6 Months
-61.93%
9 Months
-64.80%
Cellectar Biosciences Q3FY26 Results: Net loss widens to $8.0M
Net loss for Q3 2026 was $8.0 million, up from $4.4 million in Q3 2025. R&D expenses rose to $5.4 million driven by Phase 3 trial initiation. Cash position improved to $24.6 million, funding operations into Q2 2027. Loss per share narrowed to $0.46 from $1.41 due to share count increase.
2 days agoCellectar Biosciences reports 87.5% ORR in BTKi-refractory WM trial
Overall response rate reached 87.5% in BTKi-refractory WM patients. Clinical benefit rate hit 100% with median duration of response at 16.0 months. Phase 3 trial dosing expected to begin in Q1 2027 with PFS as primary endpoint. Accelerated approval application to FDA planned for H1 2027.
28 days agoCellectar to present Phase 2 data showing 79.2% major response rate
Major response rate of 79.2% and overall response rate of 87.5% observed in BTKi-refractory patients. Duration of response exceeded 16 months in the subset analysis of the Phase 2 CLOVER WaM trial. Cellectar plans to file New Drug Application for accelerated approval in 1H27. Data to be presented at International Workshop for Waldenström Macroglobulinemia in October 2026.
1mo agoBalyasny Asset Management holds 9.99% stake in Cellectar Biosciences
Balyasny Asset Management reported a 9.99% stake in Cellectar Biosciences as of June 30, 2026. The SEC 13G filing reveals the firm holds 798,382 shares and warrants, marking a substantial minority interest in the biotech firm.
3mo agoStemPoint Capital reports 9.99% stake in Cellectar Biosciences
StemPoint Capital filed an SEC Form 13G revealing a 9.99% ownership stake in Cellectar Biosciences Inc. as of June 30, 2026. The holding consists of 845,740 shares, which include pre-funded warrants.
3mo agoCellectar Q2 net loss widens 28% to $6.9M, misses EPS estimate
Cellectar Biosciences posted a Q2 2026 net loss of $6.9 million, up 28% from the prior year, driven by a 90% surge in R&D spend. The per-share loss of $(0.57) missed estimates of $(0.48). Cash balances rose to $34.0 million after a capital raise, supporting ongoing Phase 3 trials for its lead asset iopofosine I 131.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Cellectar Biosciences is now worth
$ 0.45
Resulting in a loss of
$ 99.55 (99.55%)
Note: Past profits do not guarantee future returns.
